Aktis Oncology FY Conference Summary Company Overview - **Company**: Aktis Oncology (NasdaqGS:AKTS) - **Industry**: Targeted radiopharmaceuticals, specifically in oncology - **Focus**: Development of novel radiopharmaceuticals targeting various cancer types beyond current limitations Core Insights and Arguments - **Market Potential**: The radiopharmaceutical category is approaching an inflection point with significant clinical and commercial validation, exemplified by Pluvicto being the best-launching oncology drug in a decade since Ibrance [2][20] - **Target Expansion**: Aktis aims to expand the benefits of radiopharmaceuticals to additional targets beyond the current focus on PSMA and SSTR2, which are limited to specific cancer types [2][3] - **Lead Programs**: Aktis has two lead programs: - **AKY-1189**: Targets Nectin-4 - **AKY-2519**: Targets B7-H3 - Both programs are expected to provide multi-indication and multi-disease area opportunities, potentially leading to large blockbuster drugs [4][20] - **Clinical Development**: The company is focused on generating additional clinical data over the next 1-2 years to support the advancement of these lead programs [5][19] - **Manufacturing and Supply Chain**: Aktis is building its own manufacturing facility to enhance control over the end-to-end supply chain for radiopharmaceuticals, which is currently functioning well for ongoing Phase 1b studies [6][26] Additional Important Content - **Pipeline and Technology**: Aktis has a robust pipeline beyond the lead programs, with ongoing development of additional agents and a focus on generative AI design to enhance target discovery [14][29] - **Market Size Projections**: The therapeutic segment of radiopharmaceuticals is projected to reach $6 billion-$9 billion by the end of the decade, with potential expansion to a $25 billion-$35 billion market, and upside to $60 billion depending on the number of tumor types targeted [20] - **Patient Population Expansion**: The company aims to extend the benefits of radiopharmaceuticals to a broader patient population, including those with bladder, breast, lung, and other cancers, moving beyond the current focus on prostate and rare GI tumors [22][23] - **Advisory Board Insights**: Feedback from advisory boards suggests a preference for earlier lines of treatment rather than following traditional chemotherapy, indicating a potential shift in treatment paradigms [61][64] - **Team Expertise**: The leadership team at Aktis has significant experience, with a combined history of 14 FDA approvals, enhancing confidence in the company's capabilities [27][28] Conclusion Aktis Oncology is positioned at a pivotal moment in the radiopharmaceutical industry, with innovative approaches to expand treatment options for cancer patients. The company's focus on novel targets, robust clinical development, and strategic manufacturing capabilities highlight its potential for significant impact in oncology.

Maximizing the Impact of Radiopharmaceuticals TD Cowen 46th Annual Healthcare Conference March 2026 1 Disclaimer Information in this presentation and the accompanying oral presentation contains forward-looking statements within the meaning of the Private Securities Litigation Act of 1995 that involve substantial risks and uncertainties about Aktis Oncology and the industry in which Aktis Oncology operates, including statements regarding the initiation, timing, progress, results and costs of Aktis Oncology's ...